Evidence map›Paper›PMID 24251242›Full record

ArticleTranslational medicine @ UniSa2013

The determinants of translational medicine success - a managerial contribution.

Francesco Polese, M Capunzo

Abstract read
In one paragraph

Article in Translational medicine @ UniSa, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Francesco PoleseDept. of Business Studies (Management & Information Technology), University of Salerno, Italy - ( fpolese@unisa.it ).
M Capunzo

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Scope of Translational Medicine is to speed the development of new compounds of medical protocols and/or treatments to improve patient's quality of life. Translational medicine represents the synergy between epidemiology, basic research and clinical trials, and is based upon Innovation Management and Research Development in medicine. Being the speed and progression up to the patient a key issue of Translational Medicine, the innovation process ought to be pursued according to rigorous protocols embedded on a research development path capable of decreasing the lead time at the most. Translational Medicine represents a goal to be pursued by all involved actors, from academic researchers to clinicians, patients and others than can be seen as a network of co-creating actors engaged for the ultimate patient benefit. To underpin Translational Medicine advantages and determinants, the paper approaches the issue by adopting a systems thinking perspective, capable of highlighting the key issues to be considered.

Indexed as

health networksinnovation managementservice co-creationsystems thinkingTranslational medicine

Identifiers

PMID24251242
PMCPMC3829794

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.